Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 509

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Open access
Jain, Nitin, Keating, Michael, Thompson, Philip, Ferrajoli, Alessandra, Burger, Jan, Borthakur, Gautam, Takahashi, Koichi, Estrov, Zeev, Fowler, Nathan, Kadia, Tapan, Konopleva, Marina, Alvarado, Yesid, Yilmaz, Musa, DiNardo, Courtney, Bose, Prithviraj, Ohanian, Maro, Pemmaraju, Naveen, Jabbour, Elias, Sasaki, Koji, Kanagal-Shamanna, Rashmi, Patel, Keyur, Jorgensen, Jeffrey, Garg, Naveen, Wang, Xuemei, Sondermann, Katrina, Cruz, Nichole, Wei, Chongjuan, Ayala, Ana, Plunkett, William, Kantarjian, Hagop, Gandhi, Varsha, Wierda, William·2019·New England Journal of Medicine

Abstract

BACKGROUND: Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination. METHODS: ). RESULTS: aberration, or chromosome 11q deletion. With combined treatment, the proportions of patients who had complete remission (with or without normal blood count recovery) and remission with undetectable minimal residual disease increased over time. After 12 cycles of combined treatment, 88% of the patients had complete remission or complete remission with incomplete count recovery, and 61% had remission with undetectable minimal residual disease. Responses were noted in older adults and across all high-risk subgroups. Three patients had laboratory evidence of tumor lysis syndrome. The adverse-event profile was similar to what has been reported with ibrutinib and venetoclax. CONCLUSIONS: In this study, combined venetoclax and ibrutinib was an effective oral regimen for high-risk and older patients with CLL. (Funded by AbbVie and others; ClinicalTrials.gov number, NCT02756897.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1900574

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 509

Metadata

Authors
Jain, N., Keating, M., Thompson, P., Ferrajoli, A., Burger, J., Borthakur, G., Takahashi, K., Estrov, Z., Fowler, N., Kadia, T., Konopleva, M., Alvarado, Y., Yilmaz, M., DiNardo, C., Bose, P., Ohanian, M., Pemmaraju, N., Jabbour, E., Sasaki, K., Kanagal-Shamanna, R., Patel, K., Jorgensen, J., Garg, N., Wang, X., Sondermann, K., Cruz, N., Wei, C., Ayala, A., Plunkett, W., Kantarjian, H., Gandhi, V., & Wierda, W.
Venue
New England Journal of Medicine
Published
2019-05-30
Volume
380
Issue
22
Pages
2095-2103
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2946882253
Cited by
509
References
3
FWCI
39.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ibrutinib and Venetoclax for First-Line Treatment of CLL. https://app.cochat.ai/papers/10.1056/nejmoa1900574
The paper
Jain, N., Keating, M., Thompson, P., Ferrajoli, A., Burger, J., Borthakur, G., Takahashi, K., Estrov, Z., Fowler, N., Kadia, T., Konopleva, M., Alvarado, Y., Yilmaz, M., DiNardo, C., Bose, P., Ohanian, M., Pemmaraju, N., Jabbour, E., Sasaki, K., . . . Wierda, W. (2019). Ibrutinib and Venetoclax for First-Line Treatment of CLL. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1900574

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.